Details of the Drug
General Information of Drug (ID: DMG6ZU4)
Drug Name |
Lanreotide acetate
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 1096.3 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 17 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 13 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 14 | ||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Acromegaly | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 5A60.0 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Lanreotide acetate (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. | ||||
---|---|---|---|---|---|
2 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
3 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
4 | Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ. | ||||
5 | Cerner Multum, Inc. "Australian Product Information.". | ||||
6 | Product Information. Lutathera (lutetium Lu 177 dotatate). Advanced Accelerator Applications, New York, NY. | ||||
7 | Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ. | ||||
8 | Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA. | ||||
9 | Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
10 | Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA. | ||||
11 | Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA. | ||||
12 | Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
13 | Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA. | ||||
14 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
15 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
16 | Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ. | ||||
17 | Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL. | ||||